Biopharmaceuticals Contract Manufacturing Market Worth $27.3 Billion By 2030

Biopharmaceuticals Contract Manufacturing Market Growth & Trends

The global biopharmaceuticals contract manufacturing market size is expected to reach USD 27.3 billion by 2030, growing at a CAGR of 5.2% from 2022 to 2030, according to a new report by Grand View Research, Inc. Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet the companies' demands with respect to regulatory standards and new services. The pandemic has, however, also had some negative knock-on effects as budgets and resources are diverted to “COVID products” at the expense of other biologics projects in development for other therapeutic areas.

The reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise during the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio. The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca’s COVID-19 vaccine candidate, AZD1222.

The future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd. 

 Request a free sample copy or view the report summary: Biopharmaceuticals Contract Manufacturing Market Report

Biopharmaceuticals Contract Manufacturing Market Report Highlights

• Mammalian-based biopharmaceutical contract manufacturing captured the largest market share about 58% in 2021 owing to the high penetration of mammalian expression systems for biologics development

• Out of all the services offered in this market, process development contributed to the largest share of 33% in 2021, owing to high capital investment, especially in downstream process

• Biologics contract manufacturing dominated its counterpart segment owing to higher demand for biologics production. However, the biosimilar segment is growing with a lucrative CAGR of 8.3% due to cost-saving advantages associated with biosimilars development

• The presence of an effective regulatory framework for biologics development in the U.S. has resulted in a large share of the North America market of 34.0% in 2021

• However, Asia Pacific is expected to emerge as the fastest-growing regional market with a CAGR of 5.8% from 2022 to 2030, owing to developing economies such as India and China incorporating developments to sustain the competition

Biopharmaceuticals Contract Manufacturing Market Segmentation

Grand View Research has segmented the global biopharmaceuticals contract manufacturing market based on source, service, product, therapeutic area and region: 

Biopharmaceuticals Contract Manufacturing Source Outlook (Revenue, USD Million, 2017 - 2030)

• Mammalian

• Non-mammalian

Biopharmaceuticals Contract Manufacturing Service Outlook (Revenue, USD Million, 2017 - 2030)

• Process Development

  • Downstream

  • Upstream

• Fill & Finish Operations

• Analytical & QC studies

• Packaging

Biopharmaceuticals Contract Manufacturing Product Outlook (Revenue, USD Million, 2017 - 2030)

• Biologics

  • Monoclonal antibodies (MABs)

  • Recombinant Proteins

  • Vaccines

  • Antisense, RNAi, & Molecular Therapy

  • Others

• Biosimilars

Biopharmaceuticals Contract Manufacturing Therapeutic Area Outlook (Revenue, USD Million, 2017 - 2030)

• Oncology

• Autoimmune Diseases

• Metabolic Diseases

• Cardiovascular Diseases

• Neurology

• Infectious Diseases

• Others

Biopharmaceuticals Contract Manufacturing Regional Outlook (Revenue, USD Million, 2017 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK 

  • Germany

  • France

  • Italy

    Spain

• Asia Pacific

  • China

  • India

  • Japan

  • Australia

  • South Korea

• Latin America

  • Brazil

  • Colombia

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

    UAE

List of Key Players in Biopharmaceuticals Contract Manufacturing Market

• Boehringer Ingelheim GmbH

• Lonza

• Inno Biologics Sdn Bhd

• Rentschler Biotechnologie GmbH

• JRS PHARMA

• AGC Biologics

• ProBioGen

• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

• Toyobo Co. Ltd.

• Samsung BioLogics

• Thermo Fisher Scientific, Inc.

• Binex Co., Ltd.

• WuXi Biologics

• AbbVie, Inc.

• Novartis AG

• ADMA Biologics, Inc.

• Catalent, Inc

• Cambrex Corporation

• Pfizer Inc.

• Siegfried Holding AG